HE4, a tumor biomarker approved by the US Food and Drug Administration (FDA) in 2009 and by the National Medical Products Administration (NMPA) (formerly the China FDA) in 2012 for the routine diagnostics of ovarian cancer, was found significantly elevated in patients with pSS and correlated with disease activity. Here, WFDC2 is linked to neoplasm.